Technological Advancements in Pain Management and Minimally Invasive Treatments to Drive Global Sciatica Market to USD 13.0 Bn by 2033 at 10.4% CAGR – Coherent Market Insights
The Global Sciatica Market, by Disease Type (Acute Sciatica, Chronic Sciatica, and Others), by Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) was valued at US$ 6.5 Bn in 2026 and is projected to exhibit a CAGR of 10.4% during the forecast period (2026-2033).
The key market players are focusing on the introduction of novel medicines for the treatment of sciatica, which is projected to provide a profitable opportunity for industry participants to introduce their novel products. For instance, in November 2018, Sollis Therapeutics, Inc., an Ohio-based interventional pain therapeutics company, announced that the first patient in the RePRIEVE-CM trial, a Phase III clinical trial conducted to evaluate the safety and efficacy of the extended release non-opioid, non-steroid clonidine micropellet for the treatment of sciatica pain, has been enrolled.
Browse 44 Market Data Tables and 37 Figures spread through 237 Pages and in-depth TOC on “ Global Sciatica market”- Forecast to 2033, Global Sciatica market, by Disease Type (Acute Sciatica, Chronic Sciatica, and Others), by Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)
To know the latest trends and insights prevalent in the Sciatica Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/sciatica-market-4607
The increasing prevalence of sciatica is anticipated to drive the growth of global sciatica market over the forecast period. For instance, according to the article published in the National Centre for Biotechnology Information in June 2021, sciatica has some unique epidemiologic characteristics including, no gender predominance, peak incidence take place in patients in their fourth decade, lifetime occurrence reported between 10% to 40%, an annual incidence rate of sciatica is 1% to 5% globally, and it rarely occurs before age 20 unless the patient has trauma.
Key Development
- In May 2026, Consano Bio, a clinical-stage biotechnology company initiated a Phase 1 clinical trial of C-1101, a potential first-in-class, non-opioid therapy for chronic lumbosacral radiculopathy, also known as chronic sciatica. The therapy is designed as a platelet-derived multi-protein biologic delivered through epidural injection to modulate inflammation and support cellular repair at the nerve injury site.
- In January 2026, Boston Scientific Corporation presented multiple 2026 NANS clinical updates supporting spinal cord stimulation for chronic back and leg pain, including FAST Therapy, RELIEF registry outcomes, and SOLIS randomized trial data. The company also showcased the Intracept EDGE J Stylet, designed to optimize access for basivertebral nerve ablation procedures. (Source: Boston Scientific Corporation)
- In January 2026, Abbott, multinational medical devices and healthcare company announced five-year NANS 2026 data showing its spinal cord stimulation and dorsal root ganglion technologies reduced pain-related healthcare visits in chronic pain patients. Abbott also received FDA approval for prone MRI scans across its chronic pain neuromodulation portfolio, improving diagnostic access for implanted patients. (Source: Abbott)
Key Takeaways of the global Sciatica market
- The global sciatica market is expected to exhibit a CAGR of 10.4% during the forecast period, owing to increasing research and development activities by the key players for the development and launch of novel therapeutics for the treatment of sciatica. For instance, on May 30, 2018, Seikagaku Corporation, a pharmaceutical company, initiated a phase III A Multicenter, Randomized, Double-blind, Shamcontrolled, Comparative Study of SI-6603 in Subjects with Lumbar Disc Herniation. The study is estimated to complete by November 2022.
- Chronic sciatica segment is expected to lead the global sciatica market owing to its high incidence. For instance, according to the African Journal of Pharmacy and Pharmacology report ‘Sciatica: Medical treatment or Physiotherapy’ in 2019, stated that in 2017 there were approximately 20% of individuals suffered from acute sciatic in Pakistan.
- Nonsteroidal anti-inflammatory drugs segment is estimated to account for 44.2% market share in 2026 owing to increasing product approval. For instance, in July 2018, Aurobindo Pharma Ltd. received final approval from the U.S. Food and Drug Administration to manufacture and market Ibuprofen capsules, used to relieve pain and reduce fever.
- Major players operating in the global sciatica market include Sorrento Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Jubilant Life Sciences Ltd., Hikma Pharmaceuticals PLC., Mylan N.V., Horizon Therapeutics Plc., Sun Pharmaceutical Industries Ltd., Alkem Labs, SCILEX Pharmaceuticals, Inc., Seikagaku Corporation, Kolon Life Science, Inc., Teijin Limited, and SpineThera, Inc.
Contact Us